Jiangsu Aidea Pharmaceutical Co. Ltd. has discovered new amide compounds with potential for use in the treatment of HIV infection.

Iteos Belgium SA has synthesized new tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B) and/or PTPN2 inhibitors potentially useful for the treatment of cancer.

Caregen Co. Ltd. has identified new glucagon-like peptide 1 receptor (GLP-1R) agonists potentially useful for the treatment of obesity and diabetes.

Ensem Therapeutics Inc. has disclosed new tetracyclic GTPase KRAS mutant inhibitors, particularly G12V mutant inhibitors, potentially useful for the treatment of cancer.

Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have jointly reported new antibody-drug conjugates (ADCs) comprising a bispecific antibody or antigen-binding fragments targeting V-set domain-containing T-cell activation inhibitor 1 (VTCN1, B7-H4) and tumor-associated calcium signal transducer 2 (TACSTD2; TROP2) linked to cytotoxic drug. They are described as potentially useful for the treatment of cancer.

Thryv Therapeutics Inc. has divulged new crystalline forms of serum/glucocorticoid-regulated kinase 1 (SGK1) inhibitors and maleic acid potentially useful for the treatment of atrial fibrillation, heart failure and inflammatory disorders.

Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have identified new BCL6 degradation inducers potentially useful for the treatment of autoimmune disease and cancer.

Shanghai Ruotuo Biotechnology Co. Ltd. has patented antibody-drug conjugates (ADCs) comprising bispecific antibodies targeting epidermal growth factor receptors (EGFR; ERBB; HER) and receptor tyrosine-protein kinase erbb-3 (ERBB3; HER3) linked to a cytotoxic drug through a linker intended for use in the treatment of cancer.

Changchun Genescience Pharmaceuticals Co. Ltd. has discovered salts of fibroblast growth factor receptor 2 (FGFR2) and/or fibroblast growth factor receptor 3 (FGFR3) inhibitors reported to be useful for diagnosis and treatment of cancer, achondroplasia and osteochondrodysplasia.

Shanghai Helioson Pharmaceutical Co. Ltd. has patented molecular glue degraders comprising cereblon (CRBN) binding agents acting as proto-oncogene Vav (VAV1) degradation inducers found to be potentially useful for the treatment of autoimmune disease and cancer.